Daily Medical Update

Stasis dermatitis

Thursday, July 23, 2026

🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the last 12 months.

1. Efficacy and safety of crisaborole ointment, 2%, in participants aged ≥45 years with stasis dermatitis: Results from a fully decentralized, randomized, proof-of-concept phase 2a study.

Journal of the American Academy of Dermatology (2024) - RCT

Key Findings

  • Crisaborole produced greater total sign score reduction than vehicle at week 6 by in-person assessment (-32.4% vs -18.1%; P = .0299).
  • Central dermatologist photo review showed a larger treatment separation, with -52.5% change for crisaborole versus -10.3% for vehicle (P = .0004).

📋 Practice Implication: For non-ulcerated stasis dermatitis, crisaborole may be a steroid-sparing topical option when inflammation persists despite venous-directed baseline care.

2. Stasis Dermatitis: The Burden of Disease, Diagnosis, and Treatment.

Dermatitis : contact, atopic, occupational, drug (2023) - Review

Key Findings

  • Pain, swelling, and itching were described as major contributors to poor sleep, reduced mobility, impaired daily activity, and work or leisure limitations.
  • Progression to ulceration increases morbidity, lowers quality of life, and adds health care burden, while misdiagnosis can drive avoidable treatment and hospitalization.

📋 Practice Implication: Management should pair symptom control with early venous insufficiency treatment and follow-up, because untreated stasis dermatitis can progress beyond a localized rash.

3. Stasis Dermatitis: Pathophysiology, Current Treatment Paradigms, and the Use of the Flavonoid Diosmin.

The Journal of clinical and aesthetic dermatology (2024) - Review

Key Findings

  • Diosmin was associated with improvement in stasis changes, higher ulcer healing frequency, shorter time to ulcer healing, and reduced tissue edema.
  • Reviewed flavonoid data also reported quality-of-life improvement, reduced venous symptoms, and a favorable safety profile with few mild adverse events.

📋 Practice Implication: Oral diosmin or micronized purified flavonoid fraction can be considered as an adjunct for patients with venous edema or ulcer-risk features, not as a replacement for compression.

4. Misdiagnosis of Uncomplicated Cellulitis: a Systematic Review and Meta-analysis.

Journal of general internal medicine (2023) - Meta-Analysis

Key Findings

  • Across nine studies with 1600 participants, cellulitis misdiagnosis ranged from 19% to 83%, with a pooled mean of 41% (95% CI, 28% to 56%).
  • Among misdiagnosed cases, 54% were attributed to stasis dermatitis, eczematous dermatitis, or edema/lymphedema.

📋 Practice Implication: Patients labeled with uncomplicated cellulitis, especially with chronic edema or recurrent lower-leg erythema, warrant timely reassessment before continuing antibiotics.

5. [Bilateral infectious cellulitis of the lower limbs : does it exist ?].

Revue medicale suisse (2026) - Review

Key Findings

  • Bilateral bacterial infectious dermohypodermitis was rare versus the usual unilateral presentation of cellulitis.
  • Bilateral lower-limb erythematous swelling increased concern for noninfectious alternatives such as stasis dermatitis, erythema nodosum, photodermatoses, or contact eczema.

📋 Practice Implication: Bilateral presentations should trigger a diagnostic pause and targeted venous, dermatologic, or multidisciplinary management rather than automatic bilateral cellulitis treatment.

💡 Summary

Recent stasis dermatitis evidence emphasizes diagnostic accuracy, venous-directed care, and emerging anti-inflammatory options. Crisaborole showed short-term improvement in a small randomized trial, while reviews and cellulitis-misdiagnosis data reinforce that lower-extremity erythema and edema often need reassessment for venous disease rather than reflex antibiotics.

Generated from 59 PubMed abstracts · RCTs and Meta-analyses only

Next topic: Urinary tract infections in the elderly

Unsubscribe  ·  Subscribe